Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Jim Van Meerten

SHOCKING: Why wall streets wrong for loving protagonist therapeutics stock | Mind Blowing Facts

  • Protagonist Therapeutics (PTGX) exhibits strong technical momentum, posting a 150% gain over the past 52 weeks.
  • PTGX holds a 100% “Buy” technical opinion from Barchart.
  • Despite bullish analyst sentiment and price targets up to $137, I remain cautious due to low price stability, high short interest, and erratic earnings predictions.
  • I am choosing to invest elsewhere, as PTGX’s high valuation, low growth, and speculative profile outweigh its recent momentum.

Today’s Featured Stock

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.